A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers.

Trial Profile

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs AZD 1446 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms SAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2009 Additional trial acronym (SAD) identified as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 16 May 2009 Actual patient number (110) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top